Abstract: System and method for managing migration of trusted execution environments (TEEs) based on migration policies utilizes a source migration agent in the source host computer and a destination migration agent in a destination host computer to migrate a source TEE in the source host computer to the destination host computer. A migration policy data of the source TEE is first transmitted to the destination migration agent from the source migration agent to determine whether the destination host computer satisfies migration policies specified in the migration policy data. In response to a determination that the destination host computer satisfies the migration policies specified in the migration policy data, a destination TEE is created in the destination host computer and memory pages of the source TEE are transmitted to the destination TEE. The memory pages are then restored at the destination TEE for execution.

Abstract: System and method for managing migration of trusted execution environments (TEEs) based on migration policies utilizes a source migration agent in the source host computer and a destination migration agent in a destination host computer to migrate a source TEE in the source host computer to the destination host computer. A migration policy data of the source TEE is first transmitted to the destination migration agent from the source migration agent to determine whether the destination host computer satisfies migration policies specified in the migration policy data. In response to a determination that the destination host computer satisfies the migration policies specified in the migration policy data, a destination TEE is created in the destination host computer and memory pages of the source TEE are transmitted to the destination TEE. The memory pages are then restored at the destination TEE for execution.

Abstract: The invention provides a transmucosal pharmaceutical composition comprising an active compound, a bile salt and an osmolality adjusting ingredient, wherein the osmolality adjusting ingredient generates a localized hyperosmotic environment and maintains an osmolality level for a period of time sufficient to produce hypertonicity-facilitated transmucosal transport of said active compound across the mucosal tissue. The invention also provides a solid transmucosal dosage form containing the composition, as well as a method of treatment comprising administering the same. In one embodiment, the active compound is a triptan compound, e.g., sumatriptan and zolmitriptan.